Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma

Figures & data

Table 1 Clinical Characteristics of Patients with Hepatocellular Carcinoma Treated with Durvalumab Plus Tremelimumab

Variable (16 Patients)	Levels	Frequency (%)
Age	51–60	2(12.5%)
	61–70	10(62.5%)
	71–80	4(25%)
Sex	Female	2(12.5%)
	Male	14(87.5%)
Race	Asian	4(25%)
	Hispanic	2(12.5%)
	Other	1(6.3%)
	White	9(56.3%)
History of Drinking Alcohol	No	9(56.3%)
	Yes	7(43.8%)
History of Tobacco Use	No	6(37.5%)
	Yes	10(62.5%)
Family History of Liver Cancer	No	14(87.5%)
	Yes	2(12.5%)
Personal History of non-HCC cancer	No	13(81.3%)
	Yes	3(18.8%)
Cirrhosis	No	4(25%)
	Yes	12(75%)
ECOG	0	1(6.3%)
	1	12(75%)
	2	3(18.8%)
Child Pugh Score	A	8(50%)
	B	8(50%)
Metastasis	Yes	16(100%)

Abbreviations: HCC, hepatocellular carcinoma; ECOG, Eastern Cooperative Oncology Group.

Table 2 Number of Lines of Systemic Therapy Prior to Durvalumab Plus Tremelimumab

GH Category	n	Mean ± Standard Deviation, Median (Range)	p-value
High	10	1.60 ± 1.71, 1.5 (0, 5)	0.3328
Low	6	2.67 ± 2.07, 2.5 (0, 5)

Abbreviation: GH, growth hormone.

Table 3 Categorical Variables by GH High and Low

Variable	Levels	GH: High	GH: Low	p-value
Cirrhosis	No	2(20%)	2(33.3%)	0.6044
	Yes	8(80%)	4(66.7%)
ECOG	0	0 (0%	1(16.7%)	0.217
	1	7(70%)	5(83.3%)
	2	3(30%)	0(0%)
Child Pugh Score	A	4(40%)	4(66.67%)	0.2821
	B	6(60%)	2(33.33%)

Abbreviations: GH, growth hormone; ECOG, Eastern Cooperative Oncology Group.

Table 4 Comparison of PFS and OS Between GH-High and GH-Low Patients Who Received Durvalumab Plus Tremelimumab

GH	N=16	Event	Median (95% CI) Months	3-Month Rate	6-Month Rate	p-value
PFS
High	10	8	1.87 (0.72, NE)	20% (10%, 80%)	NE	0.036
Low	6	2	NE (3.75, NE)	80 (50%, 100%)	50% (20%, 100%)
OS
High	10	6	3.94 (0.76, NE)	60% (30%-100%)	30% (10–90%)	0.030
Low	6	0	NE (NE, NE)	100% (100–100%)	100% (100–100%)

Abbreviations: GH, growth hormone; PFS, progression-free survival; OS, overall survival; NE, not evaluable.

Figure 1 Kaplan–Meier curves representing PFS and OS among GH-high and GH-low patients who received durvalumab plus tremelimumab.

Abbreviations: GH, growth hormone; PFS, progression-free survival; OS, overall survival.